ArteraAI

Dr. Daniel Spratt on Artera’s Post‑RP test: “[It] uses clinical and pathologic features + digital pathology, running AI to help ID patients at low vs high risk of recurrence and metastasis.” Thanks @UroTimes + Hannah Clarke for the feature. heyor.ca/mI71pa #ArteraAI

The Artera team will be at the Ohio and Iowa Urological Society Annual Meetings next week (March 27–28). Looking forward to connecting with urology leaders and continuing the conversation around precision prostate cancer care. #Urology #ArteraAI

How is AI transforming cancer treatment? Listen to the conversation on how AI-powered tools are helping personalize care for patients: heyor.ca/uP2kp0 #AIinHealthcare #ProstateCancer #PrecisionMedicine #ArteraAI

Excited for Dr. Lalit Patel to present new research at #USCAP2026, the largest conference for pathologists. The work explores how multimodal AI scoring from #digitalpathology can help predict nodal metastasis risk in prostate cancer. #ArteraAI

Looking to learn more about the #ArteraAI Prostate Test? Register for this webinar to get all the details about how the test works, how to incorporate it into practice, how it can help personalize treatment plans, and more. Register now: heyor.ca/1PLdC5 #prostatecancer

Next stop: @UrologyUS Prostate Cancer Academy. Looking forward to discuss advances in prostate cancer care and how AI can support smarter clinical decisions. #ProstateCancer #Urology #ArteraAI #PrecisionMedicine

The Artera team is heading to the #SESAUA Annual Meeting. Looking forward to connecting with urology leaders and continuing the conversation around AI-powered precision care in prostate cancer. #Urology #ProstateCancer #ArteraAI

Cancer rates are rising in younger adults. As detection evolves, treatment personalization must evolve too, beyond age alone to biology, tumor behavior & individual risk. Insightful read from @theNCI: heyor.ca/utrZ11 #CancerResearch #CancerCare

Wrapping up a productive week at #GU26. Proud to share new research and connect with leaders advancing AI-powered decision support in #prostatecancer care. #ArteraAI #PrecisionMedicine

ICYMI: Amanda Lowe was featured in @AuthorityMgzine's “Meet the Women Leading the AI Industry.” Proud to see her leadership in advancing responsible AI in healthcare recognized. heyor.ca/PcYC6j #AIinHealthcare #ArteraAI

Multidisciplinary case discussion for #prostatecancer highlights practice changing utility of tools like @arteraAI prostate test in guiding ADT intensification in localized disease. A clinic-ready use case stemming from the keynote #AI discussion. The @arteraAI test increases confidence for me and the patient that he gets the right amount of treatment, sparing toxicity from some and improving cancer outcomes for others. #GU26 @urotoday @OncoAlert @OncLive @PCFnews @Larvol

Dr. Wilkins external validation of digital pathology multimodal AI (MMAI)-prognostic biomarker from PhIII CHHip trial ➡️ @arteraAI MMAI high vs intermediate vs low associated with #BCR and distant metastases risk in contemporary UK localized #pcsm cohort #GU26 @OncoAlert

More evidence supporting the @arteraAI MMAI test as an independent prognostic in the post-RP sRT setting. @SagarRPatelMD #GU26

Kicking off March on the road! The Artera team will be connecting with urology and radiation oncology leaders across several meetings in the coming days. If you’re attending, we’d love to connect! #ArteraAI #ProstateCancer #Urology #RadiationOncology

Not all prostate cancer patients benefit from hormone therapy, but its side effects are real. The ArteraAI Prostate Test predicts which patients truly benefit, helping clinicians personalize treatment and avoid unnecessary toxicity. Learn more: heyor.ca/kJCP6N

Study investigates an AI-powered prognostic test in salvage radiation therapy patients. @DrPaulNguyen @DanaFarber joins @zklaassen_md @GACancerCenter to discuss the @arteraAI prostate test for post-prostatectomy BCR, which combines clinical factors with AI-analyzed digital pathology from prostatectomy specimens. #WatchNow on UroToday > bit.ly/49aLEa1

Grateful to longtime partner Howard Wolinsky for sharing his story in @statnews and helping reframe how we think about #ProstateCancer, risk, and PSA screening. It’s time for more data-driven, personalized care. Read more: heyor.ca/kk1s4S #ArteraAI #CancerCare

Big moves from OpenAI & Anthropic signal a new chapter for AI in healthcare. In cancer care, the stakes are different. That’s why we're building purpose-built multimodal AI to support smarter, faster decisions in oncology. Read more: heyor.ca/kswBME #ArteraAI

Going to #GU26? So are we. Catch the Artera team in San Francisco next week, we're looking forward to connecting and sharing our latest work in #prostatecancer. #ArteraAI

On the road again! Catch the Artera team at: ▪️Atrium Health Visiting Professor Event – Feb 20 ▪️Texas Urology Specialists Summit – Feb 20-21 Looking forward to connecting on all things prostate cancer, AI & clinical innovation. #ArteraAI #Urology #ProstateCancer

Cancer care is expensive. AI can help change that. This @MSN article highlights 5 ways AI could save patients money, including the #ArteraAI Prostate Test, which supports smarter treatment decisions and helps avoid unnecessary costs. Read more ⬇️ msn.com/en-us/news/oth…